Skip to Main Content

Paper Details

Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Neuro Oncol
44
2020
CD8, CD8+ T-cell, CT2A, CT2A GBM, CT2A GBM model, CT2A murine GBM, CT2A neoantigens, CT2A tumors, Epb4H471L, GBM, GL261, GL261 tumor, H2-, H2-Db, PD-L1, Plin2G332R, Pomgnt1R497L, RNA, TIL, TILs, glioblastoma, human, interferon-gamma, murine, neoantigen, neoantigen specific CD8+ T cells, programmed cell death ligand 1, tumor, tumor-infiltrating lymphocytes
Author NameAffiliation
Connor J LiuWashington University School of Medicine
Connor J LiuWashington University School of Medicine
Christopher A MillerThe McDonnell Genome Institute, Washington University in St Louis
David M KranzUniversity of Illinois
Gavin P DunnWashington University School of Medicine
Gavin P DunnThe Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • 1 - 6

Datasets

Release 1.2